BiotechTube

514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Staphylococcus Aureus Bacteremia

Conditions

Staphylococcus Aureus Bacteremia

Trial Timeline

May 1, 2015 → Dec 1, 2016

NCT ID
NCT02357966

About 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II

514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II is a phase 1/2 stage product being developed by XBiotech for Staphylococcus Aureus Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT02357966. Target conditions include Staphylococcus Aureus Bacteremia.

What happened to similar drugs?

2 of 4 similar drugs in Staphylococcus Aureus Bacteremia were approved

Approved (2) Terminated (0) Active (2)
✅Imipenem/cilastatinPfizerApproved
✅linezolid (Zyvox) + vancomycinPfizerApproved
🔄Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02357966Phase 1/2Completed

Competing Products

12 competing products in Staphylococcus Aureus Bacteremia

See all competitors
ProductCompanyStageHype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3
40
AZD7760AstraZenecaPhase 1/2
39
V710 + PlaceboMerckPhase 2/3
30
DaptomycinMerckPhase 2
35
Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)MerckPhase 2
35
Imipenem/cilastatinPfizerApproved
39
linezolid (Zyvox) + vancomycinPfizerApproved
43
Linezolid + VancomycinPfizerPre-clinical
26
Aurexis®Bristol Myers SquibbPhase 2
35
Aurexis® (tefibazumab)Bristol Myers SquibbPhase 2
35
blood samples + nasal swabsSanofiPre-clinical
26
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34